At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
IMG-007drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants With 50% or Greater Scalp Hair Loss
In Brief
A Phase 2 clinical trial evaluating IMG-007 for Alopecia Areata (AA). Completed, enrolled 29 participants across 17 sites in 2 countries.
Detailed Summary
The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata (AA)
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartSep 2023
First PostedSep 2023
Primary CompletionJan 2025
TodayJul 2026
First PostedSep 29, 2023
Enrollment StartSep 25, 2023
Primary CompletionJan 14, 2025
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 2.8 years ago
Interventions
IMG-007drug
Intravenous Infusion